Novo Nordisk shares climbed over 7% after the U.S. Food and Drug Administration approved its GLP-1 pill, the first of its kind to reach the market. The approval gives the Danish pharmaceutical company an early advantage in the rapidly expanding obesity treatment sector, where it competes directly with Eli Lilly. The FDA had already approved […]

The postNovo Nordisk stock rises as oral Wegovy clears FDAappeared first onRolling Out.